These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32888079)

  • 1. Autonomy begets adherence: decisions to start and persist with osteoporosis treatment after group medical consultation.
    Wilton-Clark MS; Feasel AL; Kline GA; Billington EO
    Arch Osteoporos; 2020 Sep; 15(1):138. PubMed ID: 32888079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy decisions among postmenopausal women attending a group medical consultation or a one-on-one specialist consultation at an osteoporosis center: an observational cohort study.
    Liu CS; Feasel AL; Kline GA; Billington EO
    Osteoporos Int; 2021 Jul; 32(7):1421-1427. PubMed ID: 33462652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. At Odds About the Odds: Women's Choices to Accept Osteoporosis Medications Do Not Closely Agree with Physician-Set Treatment Thresholds.
    Billington EO; Feasel AL; Kline GA
    J Gen Intern Med; 2020 Jan; 35(1):276-282. PubMed ID: 31625042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
    Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
    Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009.
    Balasubramanian A; Tosi LL; Lane JM; Dirschl DR; Ho PR; O'Malley CD
    J Bone Joint Surg Am; 2014 Apr; 96(7):e52. PubMed ID: 24695929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot randomized controlled trial of a decision aid with tailored fracture risk tool delivered via a patient portal.
    Smallwood AJ; Schapira MM; Fedders M; Neuner JM
    Osteoporos Int; 2017 Feb; 28(2):567-576. PubMed ID: 27647529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study.
    Gonnelli S; Caffarelli C; Rossi S; Di Munno O; Malavolta N; Isaia G; Muratore M; D'Avola G; Gatto S; Minisola G; Nuti R
    Aging Clin Exp Res; 2016 Jun; 28(3):459-68. PubMed ID: 26873817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of pharmacotherapy in postmenopausal osteoporosis: a longitudinal observational study.
    Pluskiewicz W; Adamczyk P; Franek E; Sewerynek E; Wichrowska H; Napiórkowska L; Stuss M; Rozwandowicz A; Drozdzowska B
    Endokrynol Pol; 2019; 70(6):473-477. PubMed ID: 31909456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of 2 fracture risk estimation processes in Alberta: a cross-sectional chart review.
    Riar S; Feasel AL; Aghajafari F; Frohlich D; Symonds CJ; Kline GA; Billington EO
    CMAJ Open; 2021; 9(2):E711-E717. PubMed ID: 34162663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-perception of fracture risk: what can it tell us?
    Litwic AE; Compston JE; Wyman A; Siris ES; Gehlbach SH; Adachi JD; Chapurlat R; Díez-Pérez A; LaCroix AZ; Nieves JW; Netelenbos JC; Pfeilschifter J; Rossini M; Roux C; Saag KG; Silverman S; Watts NB; Greenspan SL; March L; Gregson CL; Cooper C; Dennison EM;
    Osteoporos Int; 2017 Dec; 28(12):3495-3500. PubMed ID: 28861636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium.
    Fahrleitner-Pammer A; Papaioannou N; Gielen E; Feudjo Tepie M; Toffis C; Frieling I; Geusens P; Makras P; Boschitsch E; Callens J; Anastasilakis AD; Niedhart C; Resch H; Kalouche-Khalil L; Hadji P
    Arch Osteoporos; 2017 Dec; 12(1):58. PubMed ID: 28643265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study.
    Silverman SL; Siris E; Belazi D; Recknor C; Papaioannou A; Brown JP; Gold DT; Lewiecki EM; Quinn G; Balasubramanian A; Yue S; Stolshek B; Kendler DL
    Arch Osteoporos; 2018 Aug; 13(1):85. PubMed ID: 30088189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study.
    Modi A; Sen S; Adachi JD; Adami S; Cortet B; Cooper AL; Geusens P; Mellström D; Weaver JP; van den Bergh JP; Keown P; Sajjan S
    Osteoporos Int; 2018 Feb; 29(2):329-337. PubMed ID: 29110061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of antiosteoporotic medication in the Danish ROSE population-based screening study.
    Høiberg MP; Rubin KH; Holmberg T; Rothmann MJ; Möller S; Gram J; Bech M; Brixen K; Hermann AP
    Osteoporos Int; 2019 Jun; 30(6):1223-1233. PubMed ID: 30911782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Group medical consultation for osteoporosis: a prospective pilot study of patient experience in Canadian tertiary care.
    Billington EO; Feasel AL; VanDyke JL; Kline GA
    Br J Gen Pract; 2020 Nov; 70(700):e801-e808. PubMed ID: 33020167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review.
    Fardellone P; Lello S; Cano A; de Sá Moreira E; Watanabe de Oliveira R; Julian GS; Tang B
    Clin Ther; 2019 Aug; 41(8):1576-1588. PubMed ID: 31151814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy.
    Migliaccio S; Francomano D; Romagnoli E; Marocco C; Fornari R; Resmini G; Buffa A; Di Pietro G; Corvaglia S; Gimigliano F; Moretti A; de Sire A; Malavolta N; Lenzi A; Greco EA; Iolascon G
    J Endocrinol Invest; 2017 Dec; 40(12):1321-1326. PubMed ID: 28589380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture.
    Jacob L; Dreher M; Kostev K; Hadji P
    Osteoporos Int; 2016 Mar; 27(3):963-969. PubMed ID: 26519418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
    Lai PS; Chua SS; Chew YY; Chan SP
    J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.